Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 May 16;17(5):e84252.
doi: 10.7759/cureus.84252. eCollection 2025 May.

Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy

Affiliations
Case Reports

Leukocytoclastic Vasculitis With Eosinophilia in a Patient Receiving Dupilumab Therapy

Alex M Wandler et al. Cureus. .

Abstract

We present the case of a patient with a history of treated hepatitis C virus who was diagnosed with prurigo nodularis and subsequently developed leukocytoclastic vasculitis (LCV) with eosinophilia following the initiation of dupilumab therapy. A 69-year-old African American female with previously treated hepatitis C virus presented with a papular, pruritic skin eruption initially diagnosed as prurigo nodularis. Despite treatment with oral and topical corticosteroids, she experienced no improvement. Physical examination revealed numerous hyperpigmented papules on the extensor surfaces of both upper extremities, without blisters or bullae. After starting on dupilumab, she noted minimal improvement and developed new erythematous papules on the right upper extremity. A punch biopsy performed due to ongoing symptoms showed perivascular and interstitial neutrophils with numerous eosinophils, consistent with LCV with eosinophilia. Dupilumab was discontinued, and topical tacrolimus was initiated. One month later, repeat biopsy was consistent with lichen simplex chronicus, suggesting the persistence of a chronic inflammatory state following the resolution of the initial vasculitis. This patient's findings underscore the importance of recognizing a potential association between dupilumab and the development of eosinophilic conditions in the context of dupilumab therapy. The temporal relationship between the initiation of dupilumab treatment and the onset of eosinophilic LCV suggests a potential association that should be further investigated and should encourage dermatologists to remain cognizant of the development of LCV in the setting of dupilumab therapy.

Keywords: atopic disease; drug-induced eosinophilia; dupilumab dermatologic reaction; eosinophilic dermatosis; leukocytoclastic vasculitis (lcv); prurigo nodularis (pn).

PubMed Disclaimer

Conflict of interest statement

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Physical exam
Initial presentation (a, b). Clinical presentation post-dupilumab therapy (c, d). Hyperpigmented, hyperkeratotic papules with overlying excoriations, central areas of erosion, and admixed erythematous papules to the right upper extremity.
Figure 2
Figure 2. Histopathological examination of the right upper arm.
Histopathology demonstrates orthokeratosis, regular acanthosis (a), and perivascular and interstitial neutrophils with numerous eosinophils, many extending into the edematous interstitium (b, c). Perivascular fibrin and leukocytoclasia present. The infiltrate extends into subcutis and is present around adnexa. This pattern is consistent with that of LCV (hematoxylin-eosin stain). LCV: leukocytoclastic vasculitis.

Similar articles

References

    1. Dupixent FDA package insert. [ Apr; 2025 ]. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s064lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761055s064lbl.pdf
    1. A case of leukocytoclastic vasculitis in a patient on dupilumab. Bach MS, Keeling BH, Yim E. JAAD Case Rep. 2023;42:49–51. - PMC - PubMed
    1. Eosinophilic granulomatosis with polyangiitis developed after dupilumab administration in patients with eosinophilic chronic rhinosinusitis and asthma: a case report. Suzaki I, Tanaka A, Yanai R, Maruyama Y, Kamimura S, Hirano K, Kobayashi H. BMC Pulm Med. 2023;23:130. - PMC - PubMed
    1. Eosinophilia induced by blocking the IL-4/IL-13 pathway: potential mechanisms and clinical outcomes. Olaguibel JM, Sastre J, Rodríguez JM, Del Pozo V. J Investig Allergol Clin Immunol. 2022;32:165–180. - PubMed
    1. Diagnosis and management of leukocytoclastic vasculitis. Fraticelli P, Benfaremo D, Gabrielli A. Intern Emerg Med. 2021;16:831–841. - PMC - PubMed

Publication types

LinkOut - more resources